Balanced news tone
News Sentiment
GYRE sentiment intelligence
Gyre Therapeutics Inc. news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.
Price is moving more forcefully than the current news tone suggests.
81/100 classification confidence.
directly relevant articles
high-authority source matches
-7.2% over one week, -3.2% over four weeks, trend inactive, and below fair value.
Gyre Therapeutics Appoints Three New Members to its Board of Directors
Market Reaction
Price moving ahead of tone
Price is moving more forcefully than the current news tone suggests.
Sentiment Mix
Positive, neutral, negative
Relevance
Why the article matched
Sources
Coverage mix
Event Lens
What the news is about
Sentiment Trail
Score over time
News Tape
Relevant headlines
Gyre Therapeutics (GYRE) COO trades 11,000 shares, retains 700,000
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 22 Jun 2026 07:00
- Source
- Stock Titan
Gyre Therapeutics Shareholders Approve Directors and Governance Measures
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 17 Jun 2026 07:00
- Source
- The Globe and Mail
Gyre Therapeutics (NASDAQ: GYRE) investors back directors, pay and Series B conversion
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 16 Jun 2026 07:00
- Source
- Stock Titan
Gyre Therapeutics (GYRE) COO sells 2,800 shares after exercising options
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 15 Jun 2026 07:00
- Source
- Stock Titan
CEO of Gyre Therapeutics (NASDAQ: GYRE) receives 120,000 stock options
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 10 Jun 2026 07:00
- Source
- Stock Titan
There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings
- Tone
- Negative 34/100
- Event
- Earnings
- Published
- 15 May 2026 07:00
- Source
- simplywall.st
Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 14 May 2026 07:00
- Source
- Market source
Gyre Therapeutics Says China Regulator Accepts Application for Liver Fibrosis Drug
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 12 May 2026 21:53
- Source
- MT Newswires
Gyre Therapeutics Announces NMPA Acceptance of New Drug Application for F351 (hydronidone) for CHB-Induced Liver Fibrosis Treatment
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 12 May 2026 20:05
- Source
- GlobeNewswire
Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results
- Tone
- Positive 66/100
- Event
- Earnings
- Published
- 11 May 2026 07:00
- Source
- simplywall.st
Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 11 May 2026 07:00
- Source
- Market source
Gyre Therapeutics Reports First Quarter 2026 Results and Provides Business Update
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 07 May 2026 10:00
- Source
- GlobeNewswire
Gyre Therapeutics, Inc. (GYRE) Reports Q1 Loss, Lags Revenue Estimates
- Tone
- Negative 34/100
- Event
- Earnings
- Published
- 07 May 2026 07:00
- Source
- Market source
Gyre Therapeutics Completes $300 Million All-Stock Acquisition of Cullgen
- Tone
- Neutral 50/100
- Event
- Deals and strategy
- Published
- 04 May 2026 14:43
- Source
- MT Newswires
Gyre Therapeutics Completes Acquisition of Cullgen to Create U.S.- and China-based Fully Integrated Biopharmaceutical Company
- Tone
- Neutral 50/100
- Event
- Deals and strategy
- Published
- 04 May 2026 12:47
- Source
- GlobeNewswire
Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 25 Apr 2026 07:00
- Source
- Market source
Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 21 Apr 2026 07:00
- Source
- Market source
Gyre Therapeutics Enters into Agreement to Acquire Cullgen
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 02 Mar 2026 08:00
- Source
- GlobeNewswire
Pulmatrix Shares Dive As Privately-Held Pharma Company Chooses To Merge With Gyre Therapeutics Instead
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 02 Mar 2026 08:00
- Source
- Stocktwits
Can Gyre Therapeutics Stock Recover If Markets Fall?
- Tone
- Negative 34/100
- Event
- Market update
- Published
- 21 Dec 2025 08:00
- Source
- Trefis
272 Patients Enrolled — Gyre Therapeutics' Phase 3 Pirfenidone Trial Completes at 18 China Sites
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 15 Oct 2025 07:00
- Source
- Stock Titan
Gyre Therapeutics (GYRE) Stock Price, News & Analysis
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 25 Apr 2025 00:53
- Source
- Stock Titan